Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

A legfontosabb adatok

Hol
‘Aiea, Albuquerque, Alexandria, Ames, Anaconda, Ankeny, Ann Arbor, Ashland, Aurora, Battle Creek, Bellevue, Bemidji, Bend, Beverly Hills, Billings, Bismarck, Bloomington, Boise, Boone, Boston, Bozeman, Brainerd, Brighton, Burnsville, Caldwell, Canton, Cape Girardeau, Carthage, Cedar Rapids, Centerville, Centralia, Chaska, Chelsea, Chicago, City of Saint Peters, Clackamas, Clinton, Clive, Coeur d'Alene, Colorado Springs, Coon Rapids, Creve Coeur, Danville, Dayton, Decatur, Deer River, DeKalb, Des Moines, Detroit, Detroit Lakes, Dixon, Duluth, Eau Claire, Edina, Effingham, Escanaba, Eureka, Fairfax, Falls Church, Fargo, Farmington Hills, Flint, Fort Collins, Fort Dodge, Fosston, Franklin, Fridley, Fruitland, Galesburg, Geneva, Glenview, Goldsboro, Grand Rapids, Grayslake, Great Falls, Greeley, Green Bay, Greenville, Hibbing, Honolulu, Irvine, Jacksonville, Jamestown, Jefferson, Kalamazoo, Kalispell, Kewanee, La Crosse, Lake Forest, Lake Success, Lansing, Lebanon, Little Rock, Livonia, Los Angeles, Loveland, Lynchburg, Macomb, Maplewood, Marshalltown, Marshfield, Mattoon, Maywood, Meridian, Milwaukee, Mineola, Minneapolis, Minocqua, Missoula, Mukwonago, Muskegon, Nampa, New Richmond, New York, Newark, Newberg, Niles, Normal, Norton Shores, O'Fallon, Oconomowoc, Oconto Falls, Oklahoma City, Omaha, Ontario, Orange, Oregon City, Orland Park, Orlando, Ottawa, Park Rapids, Pekin, Peoria, Peru, Philadelphia, Phoenix, Pontiac, Portland, Post Falls, Princeton, Rapid City, Reed City, Rice Lake, Richmond, Rochester, Saint Johnsbury, Saint Joseph, Saint Louis Park, Saint Paul, Salt Lake City, Sandpoint, Sandstone, Sheboygan, Shiloh, Sioux Falls, Springfield, St Louis, Stevens Point, Stoneham, Sturgeon Bay, Superior, Tappahannock, Traverse City, Troy, Twin Falls, Urbana, Virginia, Waconia, Warrenville, Washington, Waukee, Waukesha, Weston, Willow Grove, Woodbury, Wyoming, Yorkville és Ypsilanti (Egyesült Államok)Mind a 232 helyszín megnézése
Fázis
2. fázis

AI-kivonat: kiket keres a vizsgálat

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek előrehaladott melanomája vagy fej-nyaki laphámrákja van, és a betegség PD-1 immunterápia alatt vagy röviddel utána súlyosbodott.

Életkor
18 éves vagy idősebb
Nem
Nemtől függetlenül csatlakozhat bárki.
A betegség stádiuma
Nem a szemből induló melanoma, amely III. vagy IV. stádiumú, műtéttel nem távolítható el, kiújult vagy szétterjedt. Vagy fej-nyaki laphámrák (garat, szájüreg, alsó garat vagy gégefő), amely helyben kiújult, sugárkezeléssel vagy műtéttel nem gyógyítható, vagy szétterjedt. Mérhető betegség szükséges.
Korábbi kezelés
A daganatnak a legalább 6 hétig adott PD-1 ellenőrzőpont-gátló kezelés alatt vagy az utolsó adag után 12 héten belül kellett nőnie. Korábban nem kaphatott anti-VEGF kezelést. A fej-nyaki nyálkahártyát legfeljebb egy korábbi fő sugárkezelés érhette.
Biomarker vagy leletérték
A daganatvizsgálathoz szükség van a PD-1/L1 kezelésre adott válasz megszűnése utáni daganatmintára (vagy kutatási biopsziára). Garatrák (oropharynx) esetén a HPV- vagy p16-státusznak ismertnek kell lennie.

A részvétel fő kizáró okai

  • Orrgarati rák vagy ismeretlen kiindulású daganat
  • Szteroidot vagy más immunszuppressziót igénylő aktív autoimmun betegség, vagy korábbi szervátültetés
  • Daganatvérzés vagy vérköhögés az elmúlt 90 napban, vagy nagy ereket átnövő daganat
  • Nem kontrollált magas vérnyomás, vagy az elmúlt 90 napban szívinfarktus vagy vérrögesemény, amely véralvadásgátlást igényelt
  • Terhesség vagy szoptatás

Gépi kiolvasás: 2026. november 12.

Helyszínek itt: Egyesült Államok

  • Hawaii Cancer Care - Westridge‘Aiea, Egyesült ÁllamokNo longer taking part
  • University of New Mexico Cancer CenterAlbuquerque, Egyesült ÁllamokContact: Moises Harari-Turquie (principal investigator)Résztvevőt keres
  • Inova Alexandria HospitalAlexandria, Egyesült ÁllamokContact: Sekwon Jang (principal investigator)Résztvevőt keres
  • Mary Greeley Medical CenterAmes, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • McFarland Clinic - AmesAmes, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • Community Hospital of AnacondaAnaconda, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • University of Michigan Rogel Cancer CenterAnn Arbor, Egyesült ÁllamokContact: Paul L. Swiecicki (principal investigator)Résztvevőt keres
  • Duluth Clinic AshlandAshland, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Rocky Mountain Regional VA Medical CenterAurora, Egyesült ÁllamokNo longer taking part
  • Rush-Copley Medical CenterAurora, Egyesült ÁllamokNo longer taking part
  • Bronson Battle CreekBattle Creek, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • Nebraska Medicine-BellevueBellevue, Egyesült ÁllamokContact: Alissa S. Marr (principal investigator)Résztvevőt keres
  • Sanford Joe Lueken Cancer CenterBemidji, Egyesült ÁllamokContact: Daniel Almquist (principal investigator)Résztvevőt keres
  • Saint Charles Health SystemBend, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Tower Cancer Research FoundationBeverly Hills, Egyesült ÁllamokContact: Inderjit Mehmi (principal investigator)Résztvevőt keres
  • Billings Clinic Cancer CenterBillings, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • Sanford Bismarck Medical CenterBismarck, Egyesült ÁllamokContact: Daniel Almquist (principal investigator)Résztvevőt keres
  • Illinois CancerCare-BloomingtonBloomington, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Saint Alphonsus Cancer Care Center-BoiseBoise, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Saint Luke's Cancer Institute - BoiseBoise, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • McFarland Clinic - BooneBoone, Egyesült ÁllamokNo longer taking part
  • Tufts Medical CenterBoston, Egyesült ÁllamokNo longer taking part
  • Bozeman Health Deaconess HospitalBozeman, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • Essentia Health Saint Joseph's Medical CenterBrainerd, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology - BrightonBrighton, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Trinity Health Medical Center - BrightonBrighton, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Minnesota Oncology - BurnsvilleBurnsville, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Saint Alphonsus Cancer Care Center-CaldwellCaldwell, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Illinois CancerCare-CantonCanton, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology - CantonCanton, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Trinity Health Medical Center - CantonCanton, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Saint Francis Medical CenterCape Girardeau, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Illinois CancerCare-CarthageCarthage, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Mercy HospitalCedar Rapids, Egyesült ÁllamokContact: Deborah W. Wilbur (principal investigator)Résztvevőt keres
  • Oncology Associates at Mercy Medical CenterCedar Rapids, Egyesült ÁllamokContact: Deborah W. Wilbur (principal investigator)Résztvevőt keres
  • Miami Valley Hospital SouthCenterville, Egyesült ÁllamokContact: Tarek M. Sabagh (principal investigator)Résztvevőt keres
  • Centralia Oncology ClinicCentralia, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Minnesota Oncology Hematology PA-ChaskaChaska, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Chelsea HospitalChelsea, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Northwestern UniversityChicago, Egyesült ÁllamokContact: Jacob Choi (principal investigator)Résztvevőt keres
  • University of IllinoisChicago, Egyesült ÁllamokContact: Ryan Nguyen (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, Egyesült ÁllamokContact: Brendan J. Knapp (principal investigator)Résztvevőt keres
  • Clackamas Radiation Oncology CenterClackamas, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Southeastern Medical Oncology Center-ClintonClinton, Egyesült ÁllamokContact: Samer S. Kasbari (principal investigator)Résztvevőt keres
  • Mercy Cancer Center-West LakesClive, Egyesült ÁllamokContact: Richard L. Deming (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - West Des Moines ClinicClive, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • Kootenai Health - Coeur d'AleneCoeur d'Alene, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • Memorial Hospital NorthColorado Springs, Egyesült ÁllamokContact: Stacey Parker-Brueggemann (principal investigator)Résztvevőt keres
  • UCHealth Memorial Hospital CentralColorado Springs, Egyesült ÁllamokContact: Stacey Parker-Brueggemann (principal investigator)Résztvevőt keres
  • Mercy HospitalCoon Rapids, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at West County HospitalCreve Coeur, Egyesült ÁllamokContact: Brendan J. Knapp (principal investigator)Résztvevőt keres
  • Carle at The RiverfrontDanville, Egyesült ÁllamokContact: Prem Sobti (principal investigator)Résztvevőt keres
  • Miami Valley Hospital NorthDayton, Egyesült ÁllamokContact: Tarek M. Sabagh (principal investigator)Résztvevőt keres
  • Premier Blood and Cancer CenterDayton, Egyesült ÁllamokContact: Tarek M. Sabagh (principal investigator)Résztvevőt keres
  • Cancer Care Specialists of Illinois - DecaturDecatur, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Decatur Memorial HospitalDecatur, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Essentia Health - Deer River ClinicDeer River, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Northwestern Medicine Cancer Center KishwaukeeDeKalb, Egyesült ÁllamokContact: Jacob Choi (principal investigator)Résztvevőt keres
  • Mercy Medical Center - Des MoinesDes Moines, Egyesült ÁllamokContact: Richard L. Deming (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • Wayne State University/Karmanos Cancer InstituteDetroit, Egyesült ÁllamokNo longer taking part
  • Essentia Health Saint Mary's - Detroit Lakes ClinicDetroit Lakes, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Illinois CancerCare-DixonDixon, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Essentia Health Cancer CenterDuluth, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Marshfield Medical Center-EC Cancer CenterEau Claire, Egyesült ÁllamokContact: Kareem H. Abdelhadi (principal investigator)Résztvevőt keres
  • Fairview Southdale HospitalEdina, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Minnesota Oncology - EdinaEdina, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Carle Physician Group-EffinghamEffingham, Egyesült ÁllamokContact: Prem Sobti (principal investigator)Résztvevőt keres
  • Crossroads Cancer CenterEffingham, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • OSF Saint Francis Hospital and Medical GroupEscanaba, Egyesült ÁllamokContact: Matthew L. Ryan (principal investigator)Résztvevőt keres
  • Illinois CancerCare-EurekaEureka, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Inova Fair Oaks HospitalFairfax, Egyesült ÁllamokContact: Sekwon Jang (principal investigator)Résztvevőt keres
  • Inova Schar Cancer InstituteFairfax, Egyesült ÁllamokContact: Sekwon Jang (principal investigator)Résztvevőt keres
  • Inova Fairfax HospitalFalls Church, Egyesült ÁllamokContact: Sekwon Jang (principal investigator)Résztvevőt keres
  • Essentia Health Cancer Center-South University ClinicFargo, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Sanford Broadway Medical CenterFargo, Egyesült ÁllamokContact: Daniel Almquist (principal investigator)Résztvevőt keres
  • Sanford Roger Maris Cancer CenterFargo, Egyesült ÁllamokContact: Daniel Almquist (principal investigator)Résztvevőt keres
  • Weisberg Cancer Treatment CenterFarmington Hills, Egyesült ÁllamokNo longer taking part
  • Cancer Hematology Centers - FlintFlint, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Genesys Hurley Cancer InstituteFlint, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Hurley Medical CenterFlint, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Genesee Hematology Oncology PCFlint, Egyesült ÁllamokNo longer taking part
  • Cancer Care and Hematology-Fort CollinsFort Collins, Egyesült ÁllamokContact: Stacey Parker-Brueggemann (principal investigator)Résztvevőt keres
  • Poudre Valley HospitalFort Collins, Egyesült ÁllamokContact: Stacey Parker-Brueggemann (principal investigator)Résztvevőt keres
  • McFarland Clinic - Trinity Cancer CenterFort Dodge, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • Essentia Health - FosstonFosston, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Atrium Medical Center-Middletown Regional HospitalFranklin, Egyesült ÁllamokContact: Tarek M. Sabagh (principal investigator)Résztvevőt keres
  • Unity HospitalFridley, Egyesült ÁllamokNo longer taking part
  • Saint Luke's Cancer Institute - FruitlandFruitland, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Illinois CancerCare-GalesburgGalesburg, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Northwestern Medicine Cancer Center DelnorGeneva, Egyesült ÁllamokContact: Jacob Choi (principal investigator)Résztvevőt keres
  • Northwestern Medicine Glenview Outpatient CenterGlenview, Egyesült ÁllamokContact: Jacob Choi (principal investigator)Résztvevőt keres
  • Southeastern Medical Oncology Center-GoldsboroGoldsboro, Egyesült ÁllamokContact: Samer S. Kasbari (principal investigator)Résztvevőt keres
  • Corewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • Trinity Health Grand Rapids HospitalGrand Rapids, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Northwestern Medicine Grayslake Outpatient CenterGrayslake, Egyesült ÁllamokContact: Jacob Choi (principal investigator)Résztvevőt keres
  • Benefis Sletten Cancer InstituteGreat Falls, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • UCHealth Greeley HospitalGreeley, Egyesült ÁllamokContact: Stacey Parker-Brueggemann (principal investigator)Résztvevőt keres
  • Saint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay, Egyesült ÁllamokContact: Matthew L. Ryan (principal investigator)Résztvevőt keres
  • Saint Vincent Hospital Cancer Center Green BayGreen Bay, Egyesült ÁllamokContact: Matthew L. Ryan (principal investigator)Résztvevőt keres
  • Miami Valley Cancer Care and InfusionGreenville, Egyesült ÁllamokContact: Tarek M. Sabagh (principal investigator)Résztvevőt keres
  • Essentia Health Hibbing ClinicHibbing, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Hawaii Cancer Care Inc - Waterfront PlazaHonolulu, Egyesült ÁllamokNo longer taking part
  • Queen's Cancer Cenrer - POB IHonolulu, Egyesült ÁllamokNo longer taking part
  • Queen's Cancer Center - KuakiniHonolulu, Egyesült ÁllamokNo longer taking part
  • Queen's Medical CenterHonolulu, Egyesült ÁllamokNo longer taking part
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, Egyesült ÁllamokContact: Warren A. Chow (principal investigator)Résztvevőt keres
  • Mayo Clinic in FloridaJacksonville, Egyesült ÁllamokContact: Arkadiusz Z. Dudek (principal investigator)Résztvevőt keres
  • Southeastern Medical Oncology Center-JacksonvilleJacksonville, Egyesült ÁllamokContact: Samer S. Kasbari (principal investigator)Résztvevőt keres
  • Essentia Health - Jamestown ClinicJamestown, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • McFarland Clinic - JeffersonJefferson, Egyesült ÁllamokNo longer taking part
  • Beacon Kalamazoo Cancer CenterKalamazoo, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • Bronson Methodist HospitalKalamazoo, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • West Michigan Cancer CenterKalamazoo, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • Logan Health Medical CenterKalispell, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • Illinois CancerCare-Kewanee ClinicKewanee, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Gundersen Lutheran Medical CenterLa Crosse, Egyesült ÁllamokContact: David E. Marinier (principal investigator)Résztvevőt keres
  • Northwestern Medicine Lake Forest HospitalLake Forest, Egyesült ÁllamokContact: Jacob Choi (principal investigator)Résztvevőt keres
  • Northwell Health/Center for Advanced MedicineLake Success, Egyesült ÁllamokNo longer taking part
  • University of Michigan Health - Sparrow LansingLansing, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon, Egyesült ÁllamokContact: Garrett T. Wasp (principal investigator)Résztvevőt keres
  • University of Arkansas for Medical SciencesLittle Rock, Egyesült ÁllamokContact: Omar T. Atiq (principal investigator)Résztvevőt keres
  • Trinity Health Saint Mary Mercy Livonia HospitalLivonia, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Cedars-Sinai Medical CenterLos Angeles, Egyesült ÁllamokContact: Inderjit Mehmi (principal investigator)Résztvevőt keres
  • Los Angeles General Medical CenterLos Angeles, Egyesült ÁllamokContact: Gino K. In (principal investigator)Résztvevőt keres
  • The Angeles Clinic and Research Institute - West Los Angeles OfficeLos Angeles, Egyesült ÁllamokContact: Inderjit Mehmi (principal investigator)Résztvevőt keres
  • USC / Norris Comprehensive Cancer CenterLos Angeles, Egyesült ÁllamokContact: Gino K. In (principal investigator)Résztvevőt keres
  • Medical Center of the RockiesLoveland, Egyesült ÁllamokContact: Stacey Parker-Brueggemann (principal investigator)Résztvevőt keres
  • Centra Alan B Pearson Regional Cancer CenterLynchburg, Egyesült ÁllamokContact: Andrew Poklepovic (principal investigator)Résztvevőt keres
  • Illinois CancerCare-MacombMacomb, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Saint John's Hospital - HealtheastMaplewood, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • McFarland Clinic - MarshalltownMarshalltown, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • Marshfield Medical Center-MarshfieldMarshfield, Egyesült ÁllamokContact: Kareem H. Abdelhadi (principal investigator)Résztvevőt keres
  • Carle Physician Group-Mattoon/CharlestonMattoon, Egyesült ÁllamokContact: Prem Sobti (principal investigator)Résztvevőt keres
  • Loyola University Medical CenterMaywood, Egyesült ÁllamokContact: Joseph I. Clark (principal investigator)Résztvevőt keres
  • Saint Luke's Cancer Institute - MeridianMeridian, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Medical College of WisconsinMilwaukee, Egyesült ÁllamokRésztvevőt keres
  • NYU Langone Hospital - Long IslandMineola, Egyesült ÁllamokContact: Ruth A. White (principal investigator)Résztvevőt keres
  • Abbott-Northwestern HospitalMinneapolis, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Marshfield Medical Center - MinocquaMinocqua, Egyesült ÁllamokContact: Kareem H. Abdelhadi (principal investigator)Résztvevőt keres
  • Community Medical CenterMissoula, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • ProHealth D N Greenwald CenterMukwonago, Egyesült ÁllamokContact: Timothy R. Wassenaar (principal investigator)Résztvevőt keres
  • Trinity Health Muskegon HospitalMuskegon, Egyesült ÁllamokNo longer taking part
  • Saint Alphonsus Cancer Care Center-NampaNampa, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Saint Luke's Cancer Institute - NampaNampa, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Cancer Center of Western WisconsinNew Richmond, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Laura and Isaac Perlmutter Cancer Center at NYU LangoneNew York, Egyesült ÁllamokContact: Ruth A. White (principal investigator)Résztvevőt keres
  • Helen F Graham Cancer CenterNewark, Egyesült ÁllamokContact: Gregory A. Masters (principal investigator)Résztvevőt keres
  • Medical Oncology Hematology Consultants PANewark, Egyesült ÁllamokContact: Gregory A. Masters (principal investigator)Résztvevőt keres
  • Providence Newberg Medical CenterNewberg, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Corewell Health Lakeland Hospitals - Niles HospitalNiles, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • Carle BroMenn Medical CenterNormal, Egyesült ÁllamokContact: Prem Sobti (principal investigator)Résztvevőt keres
  • Carle Cancer Institute NormalNormal, Egyesült ÁllamokContact: Prem Sobti (principal investigator)Résztvevőt keres
  • Cancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Cancer Care Center of O'FallonO'Fallon, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • ProHealth Oconomowoc Memorial HospitalOconomowoc, Egyesült ÁllamokContact: Timothy R. Wassenaar (principal investigator)Résztvevőt keres
  • Saint Vincent Hospital Cancer Center at Oconto FallsOconto Falls, Egyesült ÁllamokContact: Matthew L. Ryan (principal investigator)Résztvevőt keres
  • University of Oklahoma Health Sciences CenterOklahoma City, Egyesült ÁllamokContact: Vishnu Nagalapuram (principal investigator)Résztvevőt keres
  • Nebraska Medicine-Village PointeOmaha, Egyesült ÁllamokContact: Alissa S. Marr (principal investigator)Résztvevőt keres
  • University of Nebraska Medical CenterOmaha, Egyesült ÁllamokContact: Alissa S. Marr (principal investigator)Résztvevőt keres
  • Saint Alphonsus Cancer Care Center-OntarioOntario, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, Egyesült ÁllamokContact: Warren A. Chow (principal investigator)Résztvevőt keres
  • Providence Willamette Falls Medical CenterOregon City, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Northwestern Medicine Orland ParkOrland Park, Egyesült ÁllamokContact: Jacob Choi (principal investigator)Résztvevőt keres
  • AdventHealth OrlandoOrlando, Egyesült ÁllamokContact: Sajeve S. Thomas (principal investigator)Résztvevőt keres
  • Illinois CancerCare-Ottawa ClinicOttawa, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Essentia Health - Park RapidsPark Rapids, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Illinois CancerCare-PekinPekin, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Illinois CancerCare-PeoriaPeoria, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Illinois CancerCare-PeruPeru, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Jefferson Torresdale HospitalPhiladelphia, Egyesült ÁllamokNo longer taking part
  • Thomas Jefferson University HospitalPhiladelphia, Egyesült ÁllamokNo longer taking part
  • Mayo Clinic Hospital in ArizonaPhoenix, Egyesült ÁllamokContact: Arkadiusz Z. Dudek (principal investigator)Résztvevőt keres
  • Trinity Health Saint Joseph Mercy Oakland HospitalPontiac, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Providence Portland Medical CenterPortland, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Providence Saint Vincent Medical CenterPortland, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Kootenai Clinic Cancer Services - Post FallsPost Falls, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • Illinois CancerCare-PrincetonPrinceton, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Rapid City Regional HospitalRapid City, Egyesült ÁllamokContact: Abdel-Ghani Azzouqa (principal investigator)Résztvevőt keres
  • Corewell Health Reed City HospitalReed City, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • Marshfield Medical Center-Rice LakeRice Lake, Egyesült ÁllamokContact: Kareem H. Abdelhadi (principal investigator)Résztvevőt keres
  • VCU Massey Cancer Center at Stony PointRichmond, Egyesült ÁllamokContact: Andrew Poklepovic (principal investigator)Résztvevőt keres
  • VCU Massey Comprehensive Cancer CenterRichmond, Egyesült ÁllamokContact: Andrew Poklepovic (principal investigator)Résztvevőt keres
  • Virginia Cancer InstituteRichmond, Egyesült ÁllamokContact: Andrew Poklepovic (principal investigator)Résztvevőt keres
  • Mayo Clinic in RochesterRochester, Egyesült ÁllamokContact: Arkadiusz Z. Dudek (principal investigator)Résztvevőt keres
  • Dartmouth Cancer Center - NorthSaint Johnsbury, Egyesült ÁllamokContact: Garrett T. Wasp (principal investigator)Résztvevőt keres
  • Corewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • Park Nicollet Clinic - Saint Louis ParkSaint Louis Park, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Regions HospitalSaint Paul, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • United HospitalSaint Paul, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Huntsman Cancer Institute/University of UtahSalt Lake City, Egyesült ÁllamokContact: Kathleen C. Kerrigan (principal investigator)Résztvevőt keres
  • Kootenai Clinic Cancer Services - SandpointSandpoint, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • Essentia Health SandstoneSandstone, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Saint Vincent Hospital Cancer Center at SheboyganSheboygan, Egyesült ÁllamokContact: Matthew L. Ryan (principal investigator)Résztvevőt keres
  • Memorial Hospital EastShiloh, Egyesült ÁllamokContact: Brendan J. Knapp (principal investigator)Résztvevőt keres
  • Sanford Cancer Center Oncology ClinicSioux Falls, Egyesült ÁllamokContact: Daniel Almquist (principal investigator)Résztvevőt keres
  • Sanford USD Medical Center - Sioux FallsSioux Falls, Egyesült ÁllamokContact: Daniel Almquist (principal investigator)Résztvevőt keres
  • Baystate Medical CenterSpringfield, Egyesült ÁllamokContact: John C. McCann (principal investigator)Résztvevőt keres
  • Southern Illinois University School of MedicineSpringfield, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Springfield ClinicSpringfield, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Springfield Memorial HospitalSpringfield, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • Mercy Hospital SouthSt Louis, Egyesült ÁllamokContact: Jay W. Carlson (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at Christian HospitalSt Louis, Egyesült ÁllamokContact: Brendan J. Knapp (principal investigator)Résztvevőt keres
  • Siteman Cancer Center-South CountySt Louis, Egyesült ÁllamokContact: Brendan J. Knapp (principal investigator)Résztvevőt keres
  • Washington University School of MedicineSt Louis, Egyesült ÁllamokContact: Brendan J. Knapp (principal investigator)Résztvevőt keres
  • Marshfield Medical Center-River Region at Stevens PointStevens Point, Egyesült ÁllamokContact: Kareem H. Abdelhadi (principal investigator)Résztvevőt keres
  • Tufts Medical Center Cancer Center StonehamStoneham, Egyesült ÁllamokNo longer taking part
  • Saint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay, Egyesült ÁllamokContact: Matthew L. Ryan (principal investigator)Résztvevőt keres
  • Essentia Health Saint Mary's Hospital - SuperiorSuperior, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • VCU Health Tappahannock HospitalTappahannock, Egyesült ÁllamokContact: Andrew Poklepovic (principal investigator)Résztvevőt keres
  • Munson Medical CenterTraverse City, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • Upper Valley Medical CenterTroy, Egyesült ÁllamokContact: Tarek M. Sabagh (principal investigator)Résztvevőt keres
  • Saint Luke's Cancer Institute - Twin FallsTwin Falls, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Carle Cancer CenterUrbana, Egyesült ÁllamokContact: Prem Sobti (principal investigator)Résztvevőt keres
  • Essentia Health Virginia ClinicVirginia, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Ridgeview Medical CenterWaconia, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • Northwestern Medicine Cancer Center WarrenvilleWarrenville, Egyesült ÁllamokContact: Jacob Choi (principal investigator)Résztvevőt keres
  • Illinois CancerCare - WashingtonWashington, Egyesült ÁllamokContact: Bryan A. Faller (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - Waukee ClinicWaukee, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • ProHealth Waukesha Memorial HospitalWaukesha, Egyesült ÁllamokContact: Timothy R. Wassenaar (principal investigator)Résztvevőt keres
  • UW Cancer Center at ProHealth CareWaukesha, Egyesült ÁllamokContact: Timothy R. Wassenaar (principal investigator)Résztvevőt keres
  • Marshfield Medical Center - WestonWeston, Egyesült ÁllamokContact: Kareem H. Abdelhadi (principal investigator)Résztvevőt keres
  • Asplundh Cancer PavilionWillow Grove, Egyesült ÁllamokNo longer taking part
  • Minnesota Oncology Hematology PA-WoodburyWoodbury, Egyesült ÁllamokContact: David M. King (principal investigator)Résztvevőt keres
  • University of Michigan Health - WestWyoming, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
  • Rush-Copley Healthcare CenterYorkville, Egyesült ÁllamokNo longer taking part
  • Huron Gastroenterology PCYpsilanti, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti, Egyesült ÁllamokContact: Elie G. Dib (principal investigator)Résztvevőt keres

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

A vizsgálat adatai

Ki végzi
National Cancer Institute (NCI)
Azonosító
NCT05136196
A regiszteradat frissítve
2026. november 12.
Eredeti leírás
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.A teljes eredeti leírásKevesebb

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.

Bevonási feltételek: STEP 1 - SPECIMEN SUBMISSION; Participants must have histologically confirmed melanoma that is stage III or IV, unresectable, recurrent, or metastatic non-uveal melanoma OR Participants must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) that is either locally recurrent and non-amendable to curative therapy (e.g., radiation, surgery) or metastatic. The primary tumor location must be the oropharynx, oral cavity, hypopharynx, or larynx. Primary tumor site of nasopharynx (any histology) or unknown primary tumor are not eligible; Note: For participants with primary oropharyngeal cancer, human papillomavirus (HPV) or p16 status must be known prior to step 1 registration; Participants must have disease presentation consistent with measurable disease. Note: Current disease measurements will not be required until step 2 registration; Participants must have had documented progression during or within 12 weeks after the last dose of PD-1 checkpoint inhibition-based therapy. Participants must have been receiving checkpoint inhibition for a minimum of 6 weeks. Participants who recur during adjuvant anti-PD1 treatment or within 12 weeks of completion of adjuvant anti-PD1 treatment are eligible if they have measurable disease and are considered unresectable; Participants with known human immunodeficiency virus (HIV)-infection must be receiving anti-retroviral therapy and have an undetectable viral load test within 6 months prior to step 1 registration; Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load within 28 days prior to step 1 registration; Participants with a history of hepatitis C virus (HCV) infection must have no detectable viral load within 28 days prior to step 1 registration; Participants must not have an active infection requiring systemic therapy (except HBV, HCV or HIV as mentioned above); Participants must not have experienced myocardial infarction or thromboembolic event requiring anticoagulation within 90 days prior to step 1 registration, unless clinically stable with ongoing medical management; Participants must have recovered to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5 toxicities related to any prior treatments, unless adverse events are deemed clinically nonsignificant by the treating investigator or stable on supportive therapy; Participants must not have received more than one prior primary radiotherapy regimen, curative or adjuvant, to the mucosal surfaces of the head and neck, with the additional following criteria:; If the primary radiation is combined with chemotherapy, a minimum of 16 weeks will be required to have elapsed between the end of radiotherapy and step 1 registration. If the radiation is given alone, a minimum of 8 weeks will be required to have elapsed between the end of radiotherapy and step 1 registration; Additional palliative radiotherapy regimens are permitted but cannot have been administered to previously treated tissue (i.e., overlapping fields are excluded) with the exception of central nervous system (CNS) radiation and must be completed at least 4 weeks prior to step 1 registration; Treatment areas should be healed with no sequelae from radiation therapy (RT) that would predispose to fistula formation; Participants must not have received prior treatment with anti-VEGF therapies for any reason; Participants must be >= 18 years of age; Participants must have a Zubrod Performance Status 0 or 1; Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification and must be class 2B or better to be eligible for this trial; Participants must not have any known significant organ disfunction that, in the opinion of the treating investigator, may impact suitability for receiving combination nivolumab/cabozantinib treatment; Participants must be able to take oral medication without breaking, opening, crushing, dissolving or chewing capsules; Participants must not have malabsorption syndrome; Participants must not have active autoimmune disease requiring systemic steroids (equivalent of > 10mg of prednisone) or other immune suppression. Exceptions:; Type 1 diabetes mellitus; Endocrinopathy only requiring hormone replacement; Skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment; Conditions not expected to recur in the absence of an external trigger; Participants must not have received an organ allograft; Participants must not have a history of hemoptysis (defined as >= 1/2 tsp of bright red blood per day) or tumor bleeding within 90 days prior to step 1 registration; Participants must not have any of the following criteria due to the possibility of increased risk for tumor bleeding with cabozantinib therapy:; Prior carotid bleeding; Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by imaging studies; Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies; Any prior history of bleeding related to the current head and neck cancer; History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) within 3 months; Participants must not require concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel); Participants must not require anticoagulants except for the following:; Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH); Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors, rivaroxaban, edoxaban, or apixaban in participants without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week prior to step 1 registration without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor; Participants must not have evidence of preexisting uncontrolled hypertension 28 days prior to step 1 registration as documented by baseline blood pressure reading with systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg. Participants on antihypertensive therapies with controlled blood pressure are eligible; Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen; Participants must not be pregnant or nursing due to the known safety profiles of the drugs in this study. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential". In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion and vasectomy with testing showing no sperm in the semen; Have an adequate archival tissue specimen verified by the local pathologist and documented on the Pathology Review Form from a procedure obtained after the development of resistance to anti-PD-1/L1 therapy. Archival tissue must consist of tumor block or at least 1 hematoxylin and eosin (H\&E)-stained 4-5 micron slide and 20 freshly cut serially sectioned and numbered 4-5 micron unstained, uncharged slides OR; Be willing to undergo research biopsy AND have tumor accessible for biopsy based on the following criteria:; Mediastinal, laparoscopic, gastrointestinal, or bronchial endoscopic biopsies can be obtained incidentally to a clinically necessary procedure and NOT for the sole purpose of the clinical trial; Acceptable biopsy procedures are:; Percutaneous biopsy with local anesthetic and/or sedation with an expected risk of severe complications < 2%; Direct transoral biopsy (with or without local anesthetic and/or sedation) with an expected risk of severe complications < 2%; Excisional cutaneous biopsy with local anesthetic and/or sedation with an expected risk of severe complications < 2%; Biopsy with removal of additional tumor tissue during a medically necessary mediastinoscopy, laparoscopy, gastrointestinal endoscopy, bronchoscopy or craniotomy. No open surgical, laparoscopic or endoscopic procedure should be performed solely to obtain a biopsy for this protocol; Removal of additional tumor tissue during a medically necessary surgical procedure; Participants must submit whole blood for germline genomic analysis; Participants must have been offered the opportunity to participate in specimen banking; Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system; Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines; Participants with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator); STEP 2 TREATMENT REGISTRATION; Note: No tests or exams are required to be repeated for step 2 registration (Treatment). However, participants who are known to have a change in eligibility status after step 1 registration are not eligible for step 2 registration; Participants must continue to meet eligibility for step 1 registration prior to step 2 registration; Participants must have had their tumor tissue submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System prior to step 2 registration; Participants registered during stage II of the protocol must have received assignment to an open cohort from the SWOG Statistics and Data Management Center based on their biomarker screening profile (not applicable for patients registered during stage I of the protocol); Participants must have measurable disease. All measurable disease must be assessed within 28 days prior to step 2 registration. All non-measurable disease must be assessed within 42 days prior to step 2 registration. Note: All disease must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1); For melanoma participants, CT chest, abdomen and pelvis must be obtained. For HNSCC participants, CT neck and chest must be obtained. Further imaging (i.e., MR brain, CT abdomen/pelvis or extremities, bone scan) will be performed as deemed appropriate by the treating physician; Participants with treated brain metastases must have no evidence of progression on the follow-up brain imaging after central nervous system (CNS)-directed therapy; Participants must not have experienced any significant health changes that, in the opinion of the treating investigator, may impact continued suitability for receiving combination nivolumab/cabozantinib treatment; Participants with treated brain metastases must have discontinued steroid treatment at least 14 days prior to step 2 registration; Participants must not have received investigational agents or monoclonal antibodies (except Food and Drug Administration [FDA] approved supportive care antibodies, such as denosumab) within 28 days prior to step 2 registration; Participants must not have received surgery, chemotherapy, radiation therapy, biologic agents, or steroids within 14 days prior to step 2 registration; Participants must not have received administration of a live, attenuated vaccine within 30 days prior to step 2 registration. Note: Participants may have received a messenger ribonucleic acid (mRNA) or viral vector-based coronavirus disease 2019 (COVID-19) vaccine within 30 days prior to step 2 registration; Participants must not have received administration of any strong CYP3A4 inducers, such as but not limited to rifampin, carbamazepine, enzalutamide, mitotane, phenytoin and St. John's wort, within 14 days prior to step 2 registration; Participants must not have received administration of any strong CYP3A4 inhibitors, such as but not limited to clarithromycin, itraconazole, ketoconazole, grapefruit juice, indinavir, nelfinavir, ritonavir, nefazodone, saquinavir, and telithromycin, within 5 times the half-life of the CYP3A inhibitor prior to step 2 registration; Participants must have a history and physical examination performed within 28 days prior to step 2 registration; Leukocytes >= 3,000/uL (within 28 days prior to step 2 registration); Absolute neutrophil count >= 1,500/uL (within 28 days prior to step 2 registration); Platelets >= 100,000/uL (within 28 days prior to step 2 registration); Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) or =< 3 x ULN for participants with Gilbert's disease (within 28 days prior to step 2 registration); Aspartate aminotransferase (AST) =< 3 x institutional ULN (within 28 days prior to step 2 registration); Alanine aminotransferase (ALT) =< 3 x institutional ULN (within 28 days prior to step 2 registration); Urinalysis: For baseline value (no required value for eligibility); Measured (OR calculated) creatinine clearance >= 30 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to step 2 registration.

ClinicalTrials.gov NCT05136196